Clinical Trial

Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This prospective study recruited 20 healthy volunteers and 50 patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) according to clinical guidelines. Participants underwent AV45/AV-1 and AV1451 PET imaging to obtain information on Aβ protein deposition, tau protein distribution, and structural and functional information. The study aims to evaluate the value of multimodal imaging features in the diagnosis and progression assessment of AD, providing imaging evidence for novel treatment modalities such as lecanemab therapy and deep cervical vein-lymphatic anastomosis.
Trial Details
NCT Number NCT07114224
Lead Sponsor Xijing Hospital
Conditions Alzheimer Disease (AD), Cognitive Dysfunction, Cognitive Disorder, PET Imaging
Enrollment 70 participants
Start Date 2025-08-15
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-11